NASDAQ:BLUE bluebird bio (BLUE) Stock Forecast, Price & News $3.03 -0.01 (-0.33%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$2.92▼$3.1050-Day Range$3.03▼$4.0552-Week Range$2.78▼$8.58Volume3.12 million shsAverage Volume4.23 million shsMarket Capitalization$324.06 millionP/E RatioN/ADividend YieldN/APrice Target$7.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media bluebird bio MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside139.1% Upside$7.25 Price TargetShort InterestBearish24.35% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.02Based on 2 Articles This WeekInsider TradingSelling Shares$63,423 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.04) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector681st out of 961 stocksBiological Products, Except Diagnostic Industry112th out of 161 stocks 3.2 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 5 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.25, bluebird bio has a forecasted upside of 139.1% from its current price of $3.03.Amount of Analyst Coveragebluebird bio has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted24.35% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in bluebird bio has recently decreased by 1.55%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 1.7 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for bluebird bio this week, compared to 4 articles on an average week.Search InterestOnly 51 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows14 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 367% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,423.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($2.04) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About bluebird bio (NASDAQ:BLUE) Stockbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesSeptember 20, 2023 | theglobeandmail.com1 Huge Risk That Gene-Editing Stock Investors Desperately Need to KnowSeptember 20, 2023 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below Two Hundred Day Moving Average of $3.73September 25, 2023 | Stansberry Research (Ad)Experts: "NVIDIA Bubble" Could Affect Entire MarketSeveral major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.September 15, 2023 | msn.combluebird bio And 2seventy bio - Spinner And Spun: The Better Bet In Cell TherapySeptember 12, 2023 | msn.comCambridge biotech 2Seventy Bio slashes 40 percent of workforceSeptember 12, 2023 | msn.com2seventy bio to lay off 40% of workforce; CEO to step downAugust 29, 2023 | finance.yahoo.comIs Bluebird Bio a Bargain Buy in September?August 28, 2023 | finance.yahoo.comWall Street Thinks This Tiny Biotech Company Could Soar SoonSeptember 25, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,August 28, 2023 | finance.yahoo.combluebird bio, Inc. (NASDAQ:BLUE) institutional owners may be pleased with recent gains after 36% loss over the past yearAugust 24, 2023 | msn.comBluebird bio favored at Baird as sickle cell disease space gets busyAugust 24, 2023 | finance.yahoo.com1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall StreetAugust 17, 2023 | theglobeandmail.comCell and Gene Therapy Market Size: Regional Scope and Overview Report 2023-2030August 17, 2023 | bizjournals.comThe Petri Dish: NeuroBo gets new CEO, FDA gives bluebird a positive signAugust 16, 2023 | finance.yahoo.combluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell DiseaseAugust 12, 2023 | markets.businessinsider.comBluebird Bio (BLUE) Receives a Hold from RBC CapitalAugust 11, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)August 9, 2023 | finance.yahoo.combluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel RevenuesAugust 9, 2023 | markets.businessinsider.comBarclays Releases a Buy Rating on Bluebird Bio (BLUE)August 9, 2023 | msn.comA $2.8 Million Miracle Therapy Eludes Some Long-Suffering PatientsAugust 8, 2023 | finance.yahoo.combluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational ProgressAugust 8, 2023 | finance.yahoo.com2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right NowAugust 8, 2023 | msn.combluebird bio Q2 2023 Earnings PreviewAugust 5, 2023 | finance.yahoo.com1 Beaten-Down Stock That Could Soar by 89%, According to Wall StreetJuly 25, 2023 | finance.yahoo.combluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial UpdateJuly 25, 2023 | finance.yahoo.comEDIT Jul 2023 7.500 callJuly 21, 2023 | msn.combluebird bio: Potential To Have Third FDA Approved Gene Therapy In 2023See More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Company Calendar Last Earnings8/08/2023Today9/25/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.25 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+139.1%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-1,020.37% Pretax Margin-1,019.98% Return on Equity-37.89% Return on Assets-15.57% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio2.03 Sales & Book Value Annual Sales$3.60 million Price / Sales90.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book1.28Miscellaneous Outstanding Shares106,950,000Free Float104,707,000Market Cap$324.06 million OptionableOptionable Beta0.89 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 49)Pres, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 51)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 49)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 51)J.D., Chief Legal & Bus. Officer and Sec. Jess RowlandsHead of Corp. CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSr. VP of Technical Devel. & OperationsMr. Scott ShoemakerSr. VP of QualityMs. Sarah AlspachSr. VP of External AffairsMore ExecutivesKey CompetitorsMeiraGTxNASDAQ:MGTXVoyager TherapeuticsNASDAQ:VYGRHumacyteNASDAQ:HUMAAura BiosciencesNASDAQ:AURAMonte Rosa TherapeuticsNASDAQ:GLUEView All CompetitorsInsiders & InstitutionsBarclays PLCBought 193,676 shares on 9/21/2023Ownership: 0.702%Thomas J KlimaSold 922 sharesTotal: $3,494.38 ($3.79/share)Wolverine Trading LLCSold 6,100 shares on 8/23/2023Ownership: 0.000%Nuveen Asset Management LLCBought 13,546 shares on 8/16/2023Ownership: 0.288%GTS Securities LLCBought 41,554 shares on 8/16/2023Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions BLUE Stock - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price forecast for 2023? 10 Wall Street research analysts have issued 12 month target prices for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they anticipate the company's stock price to reach $7.25 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2023? bluebird bio's stock was trading at $6.92 at the beginning of 2023. Since then, BLUE shares have decreased by 56.2% and is now trading at $3.03. View the best growth stocks for 2023 here. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) issued its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The biotechnology company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.30 million. bluebird bio had a negative trailing twelve-month return on equity of 37.89% and a negative net margin of 1,020.37%. The company's revenue was up 360.0% compared to the same quarter last year. During the same period last year, the business earned ($1.29) EPS. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), Global X Genomics & Biotechnology ETF (GNOM), What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). What is bluebird bio's stock symbol? bluebird bio trades on the NASDAQ under the ticker symbol "BLUE." Who are bluebird bio's major shareholders? bluebird bio's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (15.30%), BlackRock Inc. (8.22%), Granahan Investment Management LLC (4.54%), Geode Capital Management LLC (2.08%), Credit Suisse AG (1.73%) and Dimensional Fund Advisors LP (1.30%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is bluebird bio's stock price today? One share of BLUE stock can currently be purchased for approximately $3.03. How much money does bluebird bio make? bluebird bio (NASDAQ:BLUE) has a market capitalization of $324.06 million and generates $3.60 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. How many employees does bluebird bio have? The company employs 323 workers across the globe. How can I contact bluebird bio? bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com. This page (NASDAQ:BLUE) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.